Endoscopic Resection of Early Gastric Cancer with Undifferentiated-Type Histology

Article information

Clin Endosc. 2017;50(6):511-513
Publication date (electronic) : 2017 November 30
doi : https://doi.org/10.5946/ce.2017.168
Division of Gastroenterology, Department of Internal Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Korea
Correspondence: Jie-Hyun Kim Division of Gastroenterology, Department of Internal Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine, 211 Eonju-ro, Gangnamgu, Seoul 06273, Korea Tel: +82-2-2019-3505, Fax: +82-2-3463-3882, E-mail: otilia94@yuhs.ac
Received 2017 October 21; Revised 2017 November 7; Accepted 2017 November 8.

See "Therapeutic Outcomes of Endoscopic Resection of Early Gastric Cancer with Undifferentiated-Type Histology: A Korean ESD Registry Database Analysis" by Chang Seok Bang, Jae Myung Park, Gwang Ho Baik, et al., on page [Related article:] 569-577.

Endoscopic resection (ER) has become a standard local therapy for early gastric cancer (EGC) without risk of lymph node metastasis (LNM). Although the indications for ER have been expanded to include undifferentiated-type histology, the usefulness of ER for undifferentiated EGC is still controversial, likely because of its more aggressive behavior than differentiated-type gastric cancer [1-3].

Thus, a precise histological diagnosis before ER is important, especially for undifferentiated-type EGC. If differentiated histology on prior biopsy is changed to undifferentiated-type histology after ER, the treatment strategy can also be changed [4]. Most studies on the therapeutic outcomes of ER focused on histology after ER. However, in the clinical field, the final pathology after ER may unexpectedly be reported as undifferentiated-type histology.

Approximately 15% to 20% of patients with undifferentiated-type EGC diagnosed after ER exhibit differentiated histology on biopsy prior to ER [4,5]. Undifferentiated-type EGC exhibiting a differentiated histology on biopsy is more aggressive and is associated with a lower curative resection (CR) rate than undifferentiated-type EGC, consistent with the biopsy pathology [4-6]. These reasons likely explain why Bang et al. (in this issue of Clinical Endoscopy) analyzed therapeutic outcomes of ER after dividing enrolled EGC into lesions with the expanded and beyond the expanded indications [7]. According to their results, the histological type of 46.1% of the lesions on biopsy was other than undifferentiated-type histology [7]. The histological findings varied from atypical cells to differentiated histology. The CR rate after ER was lower than that of lesions with the expanded indications, consistent with previous reports. This result is probably to be expected because the criteria for CR are stricter for undifferentiated-type EGC than for other histologies. Thus, when precise histological diagnosis prior to ER is required, magnifying endoscopy (ME) with narrow-band imaging (NBI) can be helpful. In addition, the actual biopsy site may be more important than the number of biopsies [8]. A previous study featuring histopathological mapping of undifferentiated-type EGC, which showed differentiated histology on biopsy, found that the zone of transition from differentiated to undifferentiated histology was frequently located at one or two peripheral sites of the lesion [4,8]. Thus, biopsy of several peripheral regions may assist in the diagnosis of undifferentiated-type histology prior to ER [4,8].

ER is performed with reference to the Japanese classification, that is, differentiated or undifferentiated-type histology. Poorly differentiated adenocarcinoma (PDA) and signet-ring cell carcinoma (SRC) are included within the undifferentiated-type histology. PDA is associated with higher LNM rates than other histological types of EGC, whereas SRC has a lower LNM rate than other histological types of EGC [9-12]. Thus, biological behaviors such as LNM differ between PDA and SRC, despite both being categorized as undifferentiated types of EGC.

However, when ER is performed according to current indications, the clinical outcomes of PDA and SRC do not differ significantly [13,14]. Bang et al. also showed no significant differences between PDA and SRC in terms of immediate and longterm outcomes [7]. According to previous studies, the pattern of non-CR differs between PDA and SRC. Non-CR is associated with vertical margin involvement in PDA but lateral margin involvement in SRC [13,14]. In the study of Bang et al., the proportion of vertical margin involvement was higher in PDA, while that of lateral margin involvement was higher in SRC, albeit not significantly [7]. Furthermore, PDA showed significantly more submucosal invasion than SRC [7]. Thus, the main considerations prior to ER can differ between PDA and SRC; prediction of tumor depth is important in PDA, whereas the extent of the lesion is important in SRC [8]. To predict the extent of SRC, intramucosal spreading of cancer cells can be considered [15]. The intramucosal spreading pattern of SRC can be categorized as expanding (epithelial spread) or infiltrative (subepithelial spread) [15]. Moreover, infiltrative spread was greater in cases with lateral margin involvement and more prevalent than expanding spread in cases surrounded by atrophy and intestinal metaplasia [15]. Therefore, larger ER safety margins may be necessary in cases of SRC with surrounding mucosa exhibiting atrophy or/and intestinal metaplasia, which can spread subepithelially to the margins [15]. Predictions of tumor extension using ME with NBI is inaccurate in SRC, unlike in differentiated EGC [16,17]. However, ME with NBI taking into consideration the pathologic growth pattern could facilitate the exact prediction of tumor extension in undifferentiated-type EGC [18]. Thus, for CR of undifferentiated-type EGC by ER, it is important to consider the biological characteristics of cancer cells, not simply to perform advanced endoscopy techniques such as ME with NBI. After ER, if the tumor size is within the present expanded criteria for CR, it can be sufficient for good clinical outcomes. In fact, one study investigated whether the risk of LNM or lymphovascular invasion (LVI) was increased when the difference in tumor size was >1 mm in comparison with the ER size criteria [19]. The result showed that the risk of LNM or LVI was not increased when there was a >10-mm tumor size difference from the ER size criteria in the ulcer-negative intramucosal cancer with undifferentiated-type histology [19].

Bang et al. stated that previous studies on the therapeutic outcomes of ER in undifferentiated-type EGC focused on post-ER histology, or included lesions that met only the expanded indications or criteria, which might have overestimated the therapeutic outcomes [7]. Thus, Bang et al. categorized the lesions according to pre/post ER and the expanded indications/criteria [7]. The present analysis may be helpful by describing real-world experience of the therapeutic outcomes of ER in undifferentiated-type EGC, although the results were not different from those of previous reports. However, it had better have provided readers more useful information, not analyzing simply therapeutic outcomes according to pre-/post ER and the expanded indication/criteria. The CR rate is low after ER in undifferentiated-type EGC according to many studies, including that by Bang et al. [7]. However, long-term therapeutic outcomes are acceptable if CR is performed. Nevertheless, the biological characteristics of undifferentiated-type EGC differ from those of differentiated EGC. Thus, the decision to perform ER in cases of undifferentiated-type EGC must be made carefully and in accordance with strict criteria based on the unique biological features of undifferentiated-type EGC.

Notes

Conflicts of Interest:The author has no financial conflicts of interest.

References

1. Aihara R, Mochiki E, Kamiyama Y, Kamimura H, Asao T, Kuwano H. Mucin phenotypic expression in early signet ring cell carcinoma of the stomach: its relationship with the clinicopathologic factors. Dig Dis Sci 2004;49:417–424.
2. Mita T, Shimoda T. Risk factors for lymph node metastasis of submucosal invasive differentiated type gastric carcinoma: clinical significance of histological heterogeneity. J Gastroenterol 2001;36:661–668.
3. Huh CW, Jung DH, Kim JH, et al. Signet ring cell mixed histology may show more aggressive behavior than other histologies in early gastric cancer. J Surg Oncol 2013;107:124–129.
4. Lee JH, Kim JH, Rhee K, et al. Undifferentiated early gastric cancer diagnosed as differentiated histology based on forceps biopsy. Pathol Res Pract 2013;209:314–318.
5. Min BH, Kang KJ, Lee JH, et al. Endoscopic resection for undifferentiated early gastric cancer: focusing on histologic discrepancies between forceps biopsy-based and endoscopic resection specimen-based diagnosis. Dig Dis Sci 2014;59:2536–2543.
6. Shim CN, Kim H, Kim DW, et al. Clinicopathologic factors and outcomes of histologic discrepancy between differentiated and undifferentiated types after endoscopic resection of early gastric cancer. Surg Endosc 2014;28:2097–2105.
7. Bang CS, Park JM, Baik GH, et al. Therapeutic outcomes of endoscopic resection of early gastric cancer with undifferentiated-type histology: a Korean ESD registry database analysis. Clin Endosc 2017;50:569–577.
8. Kim JH. Important considerations when contemplating endoscopic resection of undifferentiated-type early gastric cancer. World J Gastroenterol 2016;22:1172–1178.
9. Adachi Y, Yasuda K, Inomata M, Sato K, Shiraishi N, Kitano S. Pathology and prognosis of gastric carcinoma: well versus poorly differentiated type. Cancer 2000;89:1418–1424.
10. Hyung WJ, Noh SH, Lee JH, et al. Early gastric carcinoma with signet ring cell histology. Cancer 2002;94:78–83.
11. Kim DY, Park YK, Joo JK, et al. Clinicopathological characteristics of signet ring cell carcinoma of the stomach. ANZ J Surg 2004;74:1060–1064.
12. Kunisaki C, Akiyama H, Nomura M, et al. Clinicopathologic characteristics and surgical outcomes of mucinous gastric carcinoma. Ann Surg Oncol 2006;13:836–842.
13. Kim JH, Kim YH, Jung DH, et al. Follow-up outcomes of endoscopic resection for early gastric cancer with undifferentiated histology. Surg Endosc 2014;28:2627–2633.
14. Kim JH, Lee YC, Kim H, et al. Endoscopic resection for undifferentiated early gastric cancer. Gastrointest Endosc 2009;69:e1–e9.
15. Kim H, Kim JH, Lee YC, et al. Growth patterns of signet ring cell carcinoma of the stomach for endoscopic resection. Gut Liver 2015;9:720–726.
16. Nagahama T, Yao K, Maki S, et al. Usefulness of magnifying endoscopy with narrow-band imaging for determining the horizontal extent of early gastric cancer when there is an unclear margin by chromoendoscopy (with video). Gastrointest Endosc 2011;74:1259–1267.
17. Yao K, Nagahama T, Matsui T, Iwashita A. Detection and characterization of early gastric cancer for curative endoscopic submucosal dissection. Dig Endosc 2013;25 Suppl 1:44–54.
18. Horiuchi Y, Fujisaki J, Yamamoto N, et al. Accuracy of diagnostic demarcation of undifferentiated-type early gastric cancers for magnifying endoscopy with narrow-band imaging: endoscopic submucosal dissection cases. Gastric Cancer 2016;19:515–523.
19. Kim HW, Lee YJ, Kim JH, et al. The role of tumor size in surgical decision making after endoscopic resection for early gastric cancer. Surg Endosc 2016;30:2799–2803.

Article information Continued